Generic drugmaker is proposing to buyback more than 54.23 lakh equity shares at ₹1,475 each, fixes April 17, 2026 as the record date
Aurobindo Pharma’s Board has approved the generic drugmaker’s proposal to buyback more than 54.23 lakh equity shares at ₹1,475 each.
The buyback price is at a premium of more than 10% from the previous trading day’s (April2) closing price of ₹1,335.95. Aurobindo Pharma shares had touched a 52-week high at ₹1,359 each on April 1.
The buyback, for an aggregate amount of ₹800 crore, is proposed to be made from all shareholders / beneficial owners, including promoters and members of the promoter group, who hold equity shares as of the record date, on a proportionate basis through the “tender offer” route, the company said following the Board decision on Monday (April 6, 2026).
April 17, 2026 has been set as the record date for the purpose of determining the entitlement and the names of equity shareholders who would be eligible to participate in the buyback, the company said.
This is the second buyback by the company in less than two years. Previously, in July 2024 it had announced and August of the same year completed a ₹750 crore buyback of more than 51.36 lakh shares at a price of ₹1,460 each.
Under the latest buyback proposal, approved on Monday, the number of shares mentioned correspond to 0.93% of the total number of equity shares in the paid-up equity share capital, the company said. Promoters and promoter group holding, in Aurobindo Pharma, is 51.82%, while the public holding is 7.93%.
